The COVID pandemic has highlighted the need to increase vaccination in Africa
Signature(s)
Amount (.*)
€ 4,750,000
Sector(s)
Industry
: € 4,750,000
Signature date(s)
8/07/2021 : € 4,750,000
Link to source
Data sheet
Other links
News & Stories
Link to source
Other links
Inside the project
How and Why
Accessible health products and vaccines produced in Africa
Why
- Fewer than 2% of the three billion vaccine doses administered globally have been in Africa
- New manufacturing facilities on the continent are essential, as Africa currently imports 99% of its vaccines
- The COVID-19 pandemic highlighted the need to increase vaccination in Africa
How
- The vaccine production facility at the Institut Pasteur de Dakar plans to produce as many as 25 million doses of an approved COVID-19 vaccine a month by the end of 2022
- Improve investment in Africa’s health sector and boost the production and accessibility of heath products and technologies
- Support technology transfer and the creation of regional vaccine manufacturing hubs in other regions of Africa
Sectors & Countries
Story
A COVID-19 vaccine of its own for Africa
To increase vaccination rates, Africa needs to secure more doses. New manufacturing facilities on the continent are essential, as Africa currently imports 99% of its vaccines. The new vaccine production facility at the Institut Pasteur de Dakar is a key link in a vaccine strategy developed by the African Union and the Africa Centres for Disease Control and Prevention.
“Not only does this reinforce the health system, but also through this particular project it will create jobs, develop capacities in terms of knowhow and workforce, while bringing in new technology,” says Sall.
It’s very important that we have this solidarity between African countries and European countries because it helps to build up a global ecosystem for global health security.
Related media
Health Solutions: Searching for the magic pills
Vaccines get all the attention, but COVID treatments for people who get sick are just as important to end this pandemic
Health Solutions: Why risky ideas are good in a crisis
To end the pandemic and avoid future problems, we must stop being afraid of risk and start innovating in COVID vaccines and all types of other research
A COVID-19 vaccine of its own for Africa
Europe backs COVID-19 vaccine production in Africa with an investment in Senegal’s Institut Pasteur de Dakar.
What’s the impact of an impact investment?
A study supported by the EU bank examines how an impact investment is contributing to improved maternal health services for Senegalese women
Links
Related projects and stories
EIB Group opens country office in Belgium to support strategic investments in Belgian economy
The European Investment Bank (EIB) Group has opened a country office in Belgium, dedicated to sustaining strategic financing and sustainable growth in the country as a boost to the potential of the vibrant, dynamic and highly innovative Belgian business environment. The new office will be hosted in the Group’s Permanent EU Representation in Brussels and led by Torsten Brand, a dual Belgian-German national who has worked at the EIB for the past decade. The step by the Luxembourg-based EIB Group, which also includes the European Investment Fund (EIF), underscores its commitment to supporting the Belgian economy and deepening engagement with local businesses and the public sector.
Cocoa with a conscience: Funding fair and forest‑friendly beans
EIB finance helps Ivory Coast produce sustainable cocoa that avoids deforestation and child labour while improving agricultural practices
Where will we live? The urgent need for affordable housing in Estonia
The European Investment Bank is helping Estonia build and renovate homes so that families, workers, and communities can have affordable places to live.